Accuracy and Longevity of an Implantable Continuous Glucose Sensor in the PRECISE Study: A 180-Day, Prospective, Multicenter, Pivotal Trial by Steve, Bain
 Cronfa -  Swansea University Open Access Repository
   
_____________________________________________________________
   
This is an author produced version of a paper published in :
Diabetes Care
                               
   
Cronfa URL for this paper:
http://cronfa.swan.ac.uk/Record/cronfa30843
_____________________________________________________________
 
Paper:
Kropff, J., Choudhary, P., Neupane, S., Barnard, K., Bain, S., Kapitza, C., Forst, T., Link, M., Dehennis, A. & DeVries,
J. (2016).  Accuracy and Longevity of an Implantable Continuous Glucose Sensor in the PRECISE Study: A 180 Day,
Prospective Multi-center Pivotal Trial. Diabetes Care
 
 
 
 
 
 
 
 
_____________________________________________________________
  
This article is brought to you by Swansea University. Any person downloading material is agreeing to abide by the
terms of the repository licence. Authors are personally responsible for adhering to publisher restrictions or conditions.
When uploading content they are required to comply with their publisher agreement and the SHERPA RoMEO
database to judge whether or not it is copyright safe to add this version of the paper to this repository. 
http://www.swansea.ac.uk/iss/researchsupport/cronfa-support/ 
 Accuracy and Longevity of an Implantable Continuous Glucose 
Sensor in the PRECISE Study: A 180 Day, Prospective Multi-center 
Pivotal Trial 
Running title: The PRECISE-trial 
Jort Kropff, MD
1
, Pratik Choudhary MD
2
, Sankalpa Neupane MD
3
, Katharine Barnard, PhD
4
, 
Steve C. Bain, MD
5
, Christoph Kapitza, MD
6
, Thomas Forst, MD
7
, Manuela Link, MD
8
, 
Andrew Dehennis, PhD
9
 J. Hans DeVries, MD
1
  
1
Department of Endocrinology, Academic Medical Centre, University of Amsterdam, 
Amsterdam, the Netherlands; 
2King’s College London (KCL), London, UK; 3Cambridge 
University Hospitals NHS Foundation Trust, Cambridge, UK; 
4
Bournemouth University, 
Bournemouth, UK; 
5
Joint Clinical Research Facility, Swansea University, Swansea, UK; 
6
Profil, 
Neuss, Germany; 
7
Profil, Mainz, Germany, 
8
Institut für Diabetes-Technologie Forschungs- und 
Entwicklungsgesellschaft mbH an der Universität Ulm, Ulm, Germany; 
9
Research, Senseonics 
Inc., Germantown, USA 
Keywords: CGM; Continuous Glucose Monitoring; Implantable; Accuracy; Longevity; Patient 
perspective 
Content: Word count +/- 3274/ tables 3/ figures 1 
  
Correspondence to: Jort Kropff MD, Academic Medical Centre, Department of Endocrinology, 
Room F4-215, PO Box 2260, 1100DD, Amsterdam, the Netherlands 
E-mail: j.kropff@amc.nl Tel: +31205664573 
2 
 
Objective It is known that continuous glucose monitoring systems can lower mean glucose 
compared to episodic self-monitoring of blood glucose. Implantable CGM systems may provide 
additional benefits. 
Research Design and Methods We studied the Eversense (Senseonics Inc. Germantown, MD) 
implantable continuous glucose monitoring sensor in 71 participants aged 18 years and older 
with Type 1 and Type 2 diabetes in a 180 day multinational-multicenter pivotal trial. Participants 
used the CGM system at home and in-clinic. CGM accuracy was assessed during eight in-clinic 
visits with the mean absolute relative difference (MARD) for venous reference glucose values 
greater than 4.2 mmol/L as the primary endpoint. Secondary endpoints included Clarke Error 
Grid analysis and alarm performance. The primary safety outcome was device related serious 
adverse events. This trial is registered with ClinicalTrials.gov, number NCT02154126. 
Results The MARD value against reference glucose values above 4.2 mmol/L was 11.1% (95% 
confidence interval 10.5-11.7%). Clarke Error Grid analysis showed 99.2% of samples in the 
clinically acceptable error zones A and B. Eighty-one percent of hypoglycemic events were 
detected by the CGM system within 30 minutes. No device related serious adverse events 
occurred during the study. 
Conclusions Our results indicate the safety and accuracy of this new type of implantable CGM-
system and support it as an alternative for transcutaneous CGM. 
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People with diabetes frequently use fingerstick capillary glucose measurements to guide their 
dosing decisions (1). Continuous glucose monitoring systems (CGM) can provide glucose data in 
real-time and reduce the need for fingerstick testing (2). Additionally, people with diabetes can 
receive temporal information, trend information and alarms for impending hypoglycemic and 
hyperglycemic events (2). When used regularly, CGM can effectively lower mean glucose 
compared to fingerstick glucose measurements only (3). Unfortunately wear time of current 
transcutaneous CGM is low in some populations which might partially be explained by usability 
issues (4,5). Accuracy of CGM systems have improved over the years but could be improved 
further, especially in the hypoglycemic range (2). Transcutaneous CGM systems consist of a 
wired sensor containing glucose sensing enzymes, a transmitter and a display device. The wired 
sensor is placed just below the skin in the subcutaneous fat and is continuous with the transmitter 
base. The transmitter is placed in the transmitter base and sends data wirelessly to a display 
device such as a dedicated receiver or a smartphone. Several transcutaneous CGM systems are 
currently on the market (6–8). Implantable CGM systems may provide additional ease of use 
over transcutaneous CGM since frequent sensor insertions through the skin are not needed and 
the transmitter can be removed easily without the need for sensor replacement, for example 
during personal care. Furthermore, weekly sensor replacement with warm-up time and the risk of 
damage to the inserted sensor is no longer applicable. However, the need for implantation and 
removal through a minor surgical procedure imposes some discomfort on the patient. Currently 
no long term data on implanted sensor accuracy or longevity are available. 
In this multinational-multicenter European trial, we aimed to investigate the safety and accuracy 
of a new type of CGM system using an implantable glucose sensor. In addition, we assessed 
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sensor lifetime, system wear time, participant reported outcome measures and measures of 
glycemic control. 
 
Research design and Methods  
 
Study design and participants 
This was a 180 day, prospective, multicenter, pivotal trial. The study was executed between 
November 2014 and November 2015 and performed at seven clinical sites in Europe. 
Participants were 18 years or older and had a clinically confirmed diagnosis of type 1 or type 2 
diabetes mellitus for over one year and used insulin therapy. People were excluded from study 
participation if they had any of the following: a history of severe hypoglycemia, diabetic 
ketoacidosis, symptomatic coronary artery disease, unstable angina, myocardial infarction or 
stroke in the past 6 months prior to study, known severe microvascular complications including 
proliferative diabetic retinopathy, macular edema, active non-proliferative retinopathy and renal 
failure, a hematocrit above 50% or below 30%, lactation, pregnancy or intending to become 
pregnant during the course of the study or a condition likely to require magnetic resonance 
imaging (MRI). 
A study design diagram is given in supplementary data S1. The study consisted of eleven clinic 
visits: a screening visit, a sensor insertion visit, five 24-hour and three 8-hour device 
performance assessment visits, and a sensor removal visit. Finally, a follow-up visit was planned 
two weeks after sensor removal. The study was performed in accordance with the Declaration of 
Helsinki and was approved by the institutional ethics review board at each site. Written and 
verbal informed consent was given by all participants.  
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Procedures  
During the screening visit, laboratory measurements, a physical examination and an 
electrocardiogram (ECG) were performed. Participants received training in the use of study 
devices and written instruction materials were provided. At the sensor insertion visit, a glucose 
sensor for continuous glucose measurement was implanted in both upper-arms of the participant. 
Participants were free to choose the exact location of sensor implantation within the upper-arm 
region. Participants decided which of the two implanted sensors was to be designated as the 
primary sensor. Further information on the insertion and removal procedure is given in study 
supplementary data S2. Participants were asked to wear the transmitter over the primary sensor 
and to perform calibration twice daily using the study self-monitoring of blood glucose device 
(SMBG, Accu-Chek Aviva, Roche Diagnostics, Mannheim, Germany). The secondary sensor 
was used and calibrated during the eight device performance assessment visits only. Participants 
and study personnel were display-blinded to CGM glucose values during the device performance 
assessment visits. For the remainder of the study, continuous glucose data was available to the 
participants. Participants were asked to confirm the CGM glucose reading using the study 
SMBG device before making treatment decisions. The maximum study participation was 180 
days depending on end of sensor life which was indicated on the CGM display. The sensor was 
replaced if sensor functionality was found to be lost due to electronics or mechanical failure prior 
to visit 7 (study day 90). 
Study visits started with a glucose measurement ensuring that current blood glucose was <16.7 
mmol/L or 300 mg/dL, and ketone blood content ≤0.6mmol/L. Safety laboratory tests were 
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performed according to local clinic standard operating procedures. Body temperature (99.5
◦
F or 
<37.5
◦
C) was registered. If needed visits were rescheduled. During each study visit, venous 
plasma samples were taken for determination of dexamethasone concentration to investigate 
possible systemic absorption of dexamethasone used in the sensor system. This was done in a 
highly sensitive liquid chromatography-tandem mass spectrometry method, with a lower limit of 
detection of 2 ng/mL (9). Venous blood samples were taken every 15 minutes or more frequently 
during episodes of hypoglycemia (≤4.4 mmol/L or 80 mg/dL reference glucose) using an IV-line 
inserted in the dorsal or cubital vein of the participant’s arm. During night-time (2300-0700h), 
samples were collected every two hours. After bedside centrifuge and visual check for dilution 
and hemolysis, venous plasma glucose samples were analyzed using a YSI 2300 STAT PLUS 
glucose and lactate analyzer (YSI, Yellow Springs, OH, USA). Samples were kept on ice and 
stored in tubes containing dipotassium EDTA to allow for re-analyses. Induction of 
hypoglycemia and hyperglycemia was performed in a part of the participants per decision of the 
site investigator (39 completed in 23 subjects). Finally, visits for sensor removal and follow-up 
were performed. Insertion and sensor removal sites were inspected. Adverse events were 
registered throughout the study. Participants were asked to complete questionnaires at the start, 
after 90 days and at the end of the study. 
The continuous glucose monitoring system (Senseonics Incorporated, Germantown, MD, USA) 
used in this study consisted of three components, an implantable fluorescence-based cylindrical 
glucose sensor sized 3x16 mm, a smart transmitter sized 40x40x14 mm and a handheld device 
(iPod Touch, Apple Inc. CA, USA) running a mobile medical application. The transmitter had to 
be worn over the implanted sensor for continuous read-out of glucose data but could be removed 
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and re-placed without the need for sensor replacement. The transmitter stored the glucose data 
and provided the participants with on-body vibrations for notification of hypoglycemia and 
hyperglycemia. Data was continuously transferred to the iPod per secured low-energy Bluetooth 
transmission which allowed participants and study staff to review current and historical glucose 
data in real-time. Further product information can be found in study supplementary data S2. 
 
Outcomes 
Primary, secondary and exploratory outcomes, were predefined in a statistical analysis plan, 
additional analyses were added as indicated. The primary efficacy endpoint was the mean 
absolute relative difference (MARD) for reference glucose values greater than 4.2 mmol/L (75 
mg/dL), defined as the average of the absolute difference of paired CGM system and YSI 
readings (reference) divided by the YSI reading multiplied by 100 (10). The secondary efficacy 
endpoints included Clarke Error Grid analyses and alarm performance. Alarm performance was 
defined as confirmed and missed event detection rates and true and false alarm rates given for 
low and high glucose alarm (<3.9 mmol/L and >10 mmol/L or <70 mg/dL and >180 mg/dL). 
Confirmed event detection rate was defined as a CGM measurement beyond the alarm threshold 
within 30 minutes from the start of the event, expressed as the percentage of total number of 
events. The true alarm rate was defined as a CGM measurement beyond the alarm threshold 
confirmed by a YSI measurement within 30 minutes expressed as percentage of the total number 
of alarms. The missed event detection rate and false alarm rate were defined as the inverse of the 
confirmed event detection rate and true alarm rate, respectively. Primary safety endpoint was 
incidence of device-related or procedure-related serious adverse events, secondary safety 
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endpoints included all device-related or procedure-related adverse events. Quality of life was 
assessed using the Short Form Health Survey (SF-36) and a device specific questionnaire 
developed for the study. Exploratory outcomes included sensor lifetime analyzed using Kaplan-
Meier analysis, calibration stability, sensor stability, accuracy (MARD) over sensor life, system 
lag time, within subject precision and person to person variability. Additional analyses included 
MARD over the full glycemic range (2.2-22.0 mmol/L or 40-400 mg/dL) and over the 
hypoglycemic, normoglycemic and hyperglycemic ranges (≤4.2 mmol/L, 4.2-10 mmol/L, >10 
mmol/L or ≤75 mg/dL, 76-180 mg/dL, >180 mg/dL), system wear-time and glycemic control 
assessed per HbA1c measurement at the first and last study visit. Also real-time re-analyses of 
the raw study data using a new data algorithm and analysis of change in HbA1c over the study 
duration based on HbA1c strata <7.5% and ≥7.5% (58 mmol/mol) was performed. 
 
Statistical analysis & Power calculation 
An intention-to-treat analysis for the primary efficacy analysis and additional outcome measures 
was performed based on all evaluable data from all participants with at least one paired glucose 
reading. We reported variables as mean with standard deviation or median with interquartile 
range where appropriate. Confidence intervals for the paired difference (Δ) between outcomes 
were computed. All reported p-values are two-tailed, and values <0.05 were considered 
statistically significant. Sensor failures due to mechanical or electronical failure, for which 
processes of improvements have been implemented, were excluded from sensor life analyses. 
Impact of a new data algorithm on the system performance was assessed through re-analyses of 
the raw study data. 
9 
 
Power calculation was based on a test of superiority over a pre-specified performance goal of 
20% MARD (reference glucose values >4.2 mmol/L or >75 mg/dL) with a conservative estimate 
of the investigational device performance of MARD <18%, a standard deviation of ≤14%, a 
power of 80% and a one sided significance level of 0.0125. Considering within-subject 
correlation, data distribution, expected drop-out percentage of 20% and inclusion of up to 7 
training subjects the total required number of participants was estimated 82. SAS® 9.1, 
IBM/SPSS Version 21 and Cytel Version 10 were used for statistical analyses. This trial is 
registered with ClinicalTrials.gov, identification number NCT02154126. 
 
Results 
Eighty-one participants were included of which 5 were used for platform and procedure 
evaluation, 5 were designated for site training (further information can be found in 
supplementary data S3). The intention-to-treat analyses of the primary efficacy outcome 
included 71 patients. Participant baseline characteristics are given in table 1.  
The primary efficacy outcome over the study duration showed a MARD for reference samples 
>4.2 mmol/L of 11.1% (95%CI 10.5 - 11.7%). Performance of the CGM system in the 
hypoglycemic range (≤4.2 mmol/L or ≤75 mg/dL) was less than the overall performance (2.2-
22.0 mmol/L or 40-400 mg/dL), 21.7% versus 11.6% MARD (p< 0.001). A statistically 
significant reduction of CGM accuracy occurred in the last month of use (Table 2). Table 3 
provides further data on the accuracy of the continuous monitoring system per glycemic range. 
Real-time re-analyses of the raw study data using a new data algorithm indicated improved 
performance over the currently used algorithm (MARD 2.2-22.0 mmol/L (40-400mg/dL); 10.5% 
vs. 11.6%, 95%CI of Δ -1.1%; -0.9%, p< 0.001; MARD ≤4.2 mmol/L; 18.6 vs 21.7%, 95%CI of 
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Δ -3.8%; -2.3%, p< 0.001). Further information can be found in the study supplementary data 
S7. A Kaplan-Meier analysis for sensors survival estimated 100%, 82% and 40% of sensors 
functional through day 45, day 90 and day 180 in-clinic evaluation sessions, respectively (figure 
1, median sensor life 149 days, IQR 97; 180). Twelve sensors were considered censored in the 
survival analysis due to either subject withdrawing consent (n=6) or electronic or mechanical 
failure (n=6), five sensors were replaced due to electronic or mechanical failure within 3 months 
after study start. 
HbA1c improved in the study group from 7.54% (59 mmol/mol) at baseline to 7.19% (55 
mmol/mol) at end of study (Δ 0.35% (4 mmol/mol); 95%CI Δ -0.55% (6 mmol/mol); -0.21% (2 
mmol/mol), p<0.001. A post-hoc analyses of participants with a baseline HbA1c <7.5% (58 
mmol/mol) showed unchanged HbA1c at the last study visit (-0.04%; 95%CI Δ -0.21%; 0.14%, 
p=0.669) (-0 mmol/mol; 95%CI Δ -2 mmol/mol; 2 mmol/mol) whereas participants with a 
baseline HbA1c ≥7.5% (58 mmol/mol) showed a reduction of -0.66% (95%CI Δ -0.91%; -
0.42%, p<0.001) (-7 mmol/mol; 95%CI Δ -10 mmol/mol; -5 mmol/mol). The clinical 
performance of the CGM-system estimated per Clarke Error Grid analysis showed 99.2% of 
samples in the clinically acceptable error zones A (84.3%) and B (14.9%) (supplementary data 
S4). The in-clinic alarm performance for the hypoglycemia (<3.9 mmol/L or <70 mg/dL) and 
hyperglycemia (>10 mmol/L or >180 mg/dL) threshold indicated a confirmed detection rate of 
81% and 88%, and an event true rate of 67% and 90% respectively (supplementary data S4). No 
indication for change in glucose variability over time was found (data not shown). Transmitter 
wear compliance was a median 23.5 hours per day (IQR: 23.2; 23.7). 
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Quality of life measured per SF-36 questionnaire demonstrated unchanged quality of life scores 
from baseline to end of study. Results from a study specific questionnaire indicated high device 
acceptance with 84% rating ‘I would want to be inserted with a sensor again’ and 90% rating 
‘Using the system helped minimize the burden of diabetes in my life’ a score of 5 or higher 
(scoring range 1-7 points).  
The primary safety outcome showed no severe procedure or device related serious adverse 
events. Fourteen device or procedure-related non-severe adverse events occurred in 11 out of 71 
patients with a total number of 147 sensors implanted, used and removed. Five cases of skin 
reaction were recorded. In all cases, therapy could be continued after a temporary stop of 1-3 
weeks. Two cases of incision site infection occurred, one patient received antibiotic treatment, 
the other infections resolved without need for further medical intervention. Four participants 
withdrew consent because of study burden (n=2) and inability to obtain venous access (n=2), two 
subjects withdrew consent due to an adverse event thought to be unrelated to the device. 
Implantation and removal of sensors was performed by non-surgically trained doctors 
(endocrinologist/MDs) in most sites (5 out of 7), the remaining sites (2 out of 7) used non-
surgically trained doctors or surgeons depending on daily availability. No level of 
dexamethasone was measured in any of the venous samples. Further information on safety and 
adverse events and non-primary outcomes can be found in the study supplementary data S4. 
 
Conclusions 
The present study, investigating the accuracy, longevity and impact on patients experience of a 
novel implantable CGM system, showed safety and accurate performance of the investigational 
device over the full sensor life. Participants acceptance of the device was high. The current 
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system was accurate with an overall MARD of 11.1% for samples above 4.2 mmol/L (75 
mg/dL). CGM performance was less in the hypoglycemic range as is also seen with other CGM 
products (7,8,11,12). A limited but statistically significant reduction of CGM measurement 
accuracy occurred in the last month of use, possibly due to long term degradation of the glucose 
indicating gel before end of sensor life was reached. 
Device use coincided with a significant reduction in Hb1Ac, consistent with results of a meta-
analysis showing that HbA1c lowering with CGM use depends on baseline HbA1c and device 
wear-time (3). The Clarke Error Grid analysis estimated high clinical performance with 99.2% of 
samples in the clinically acceptable error zones A and B.  
Results from questionnaire data indicated high participant acceptance of the system but did not 
register improved perceived generic quality of life as assessed per SF36 questionnaire. 
Nonetheless study participants did describe the ease of use, ability to remove the transmitter 
without removing the sensor and availability of on-body vibration alerts as beneficial features of 
the system. Participants used the CGM for more than 23 hours per day over the full study 
duration, indicating high acceptance of the system. The implantation, use and removal of 147 
glucose sensors in 71 participants resulted in a limited number of mild to moderate skin reactions 
and skin infections, no device or procedure related serious adverse events were reported. 
A previous implantable glucose sensor was described by Garg and colleagues (13), although the 
authors described acceptable accuracy and longevity of this approach, this CGM system was 
never commercialized perhaps due to acceptability issues with the surgical implantation 
procedure related to the sensor size (similar to an AA-battery) (13). Other investigators have 
shown proof of concept of an implantable self-powered CGM in animals, but no human data is 
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available (14). Currently no implantable glucose sensors are on the market. Based on the results 
of this study, the Eversense implantable sensor received a CE mark on May 10, 2016. 
The multicenter approach with real-life use of the system at home and the long duration of the 
study allowed for assessment of glycemic outcomes, device acceptance and impact on quality of 
life on top of system performance. It should be noted that these are uncontrolled observational 
data. As in most studies testing novel diabetes technology, it can be expected that a more 
technology enthusiastic population was included in the study. Also, participants with type 2 
diabetes and participants of non-Caucasian descent were underrepresented in this study, as such 
one should be careful to directly translate the outcomes of the current study to the wider 
population.  
Based on mathematical models it was recently proposed that an inaccuracy of less than 10% 
MARD is not expected to lead to further improvements in clinical outcomes of CGM use (2), 
although this might be negated by future trials with clinically relevant outcomes. This and 
competing products are approaching the 10% mark, except for the hypoglycemic range, for 
which improvements are needed. Results from a real-time re-analyses of the raw study data using 
a new data algorithm indicated improved performance over the currently used algorithm. The 
CGM system including the new algorithm is currently investigated in a 90 day United States 
pivotal trial (ClinicalTrials.gov identifier: NCT02647905). 
The results from this study indicate that the use of a long term implantable continuous glucose 
sensor is both effective and safe and provides specific usability benefits. The results support 
implantable CGM as a worthy alternative to current transcutaneous CGM. 
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Figure references 
Figure 1. Sensor survival per Kaplan-Meier analyses 
Sensor survival is given per individual sensor per Kaplan-Meier analyses. The 71 primary 
sensors were included in the survival analyses. End of sensor lifetime is indicated by the CGM-
system. Median sensor lifetime is 149 days. 
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Tables 
 
Table 1. baseline patient characteristics  
Variable 
ITT population 
(n=71) 
Age (years) (SD) 41.7 (12.6) 
Sex  
 male (n) (%) 42 (59.2) 
 female (n) (%) 29 (40.8) 
Type 1 Diabetes Mellitus (n) (%) 66 (93.0) 
Type 2 Diabetes Mellitus (n) (%) 5 (7.0) 
Diabetes duration (years) (SD) 22.2 (12.5)  
Insulin delivery mode, CSII (n) (%) 42 (59.2) 
Body mass index (BMI) (kg/m2) (SD) 27.0 (4.2) 
HbA1c (%) (SD) 7.6 (1.1)  
HbA1c (mmol/mol) (SD) 60 (12)  
Any history of  
  Ketoacidosis (n) (%) 15 (21.1) 
  Severe hypoglycemia (n) (%) 17 (23.9) 
  Long term diabetes complications   
    retinopathy (n) (%) 16 (22.5) 
    nephropathy (n) (%) 0 (0) 
    neuropathy (n) (%) 7 (9.9) 
    cardiovascular disease (n) (%) 21 (29.6) 
    foot problems (n) (%) 4 (5.6) 
For categorical variables n (%) is presented. For continuous variables mean (SD) is presented. 
CSII: continuous subcutaneous insulin infusion 
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Table 2. Accuracy of the continuous monitoring system versus YSI over time 
 Sensor accuracy, MARD (%) over the range of 2.2-22 mmol/L or 40-400 
mg/dL 
Day MARD% (n) SD 95%CI 
15mg/dL;20%* - 
transitioning at 
75mg/dl 
0-180 
 
11.6 (21527) 11.2 11.5; 11.8 84.0% 
1−30 11.6 (10761)  11.4 11.4; 11.8 83.9% 
31−60 11.2 (4382)  9.8 10.9; 11.5 85.5% 
61−90 11.4 (1429) 10.5 10.9; 11.9 84.3% 
91−120 11.9 (2672)  11.6 11.5; 12.3 82.6% 
121−150 12.0 (975)  12.6 11.2; 12.8 84.3% 
151-180 12.9 (1308)  12.6 12.2; 13.6 81.9% 
MARD, mean absolute relative difference between device measurement and reference 
measurement. In-clinic accuracy is assessed per venous YSI reference measurement. 
*Performance of the Sensor stability was assessed by calculating the percentage of system 
readings within 15 mg/dL (for YSI ≤ 4.2 mmol/L or 75 mg/dL) or 20% (for YSI > 4.2 mmol/L or 
75 mg/dL) of the paired YSI values. 
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Table 3. Accuracy of the continuous monitoring system per glycemic range and rate of change 
 
 Sensor accuracy, MARD (%) 
 Glycemic range   Rate of Change  
Venous 
mmol/L 
(mg/dL) 
MARD (n) 
MAD (n) SD 95%CI  
Venous 
mmol/L/min 
(mg/dL/min) 
Mean 
mmol/L (n) 
(mg/dL) SD     95%CI 
≤4.2 
(75) 
21.7 (1057) 
14.2 (1057) 
 
 
21.5 
13.5 
20.4; 23.0 
13.4; 15.0 
 Decreasing glucose  
< -0.055 
(-1)  
15.6 (1964) 
280 
16.5 14.9; 16.3 
4.2-10.0 
(75-180) 
11.9 
(14274) 
-- 
10.9 
-- 
11.8; 12.1 
-- 
 Stable glucose 
-0.055;0.055 
(-1; 1) 
10.7 
(14909) 
193 
10.0 10.5; 10.8 
>10.0 
(180) 
9.2 (6196) 
-- 
7.8 
-- 
9.0; 9.4 
-- 
 Increasing glucose 
>0.055 
(1) 
13.6 (2443) 
245 
10.7 13.2; 14.1 
MARD, mean absolute relative difference between device measurement and reference 
measurement. Accuracy is assessed per venous YSI reference measurements. 
